1 week ago
Definium Therapeutics (DFTX) Stock Soars 20% on Successful Phase 3 Anxiety Trial Results
Definium Therapeutics (DFTX) stock rose 20% after DT120 ODT met Phase 3 endpoints for GAD treatment. NDA submission planned for H1 2027.
The post Definium Therapeutics (DFTX) Stock Soars 20% on Successful Phase 3 Anxiety Trial Results appeared first on Blockonomi.
Source: Blockonomi →Related News
- 29 minutes ago
HSBC Upgrades European Stock Outlook, Raises STOXX 600 Price Targets
- 30 minutes ago
CoreWeave (CRWV) Stock Gains Momentum After UBS Initiates Coverage with $120 Tar...
- 36 minutes ago
Best Buy and Amazon Forge Deeper Alliance in Connected TV Advertising Space
- 37 minutes ago
Palantir (PLTR) Stock Eyes Federal Aviation Administration AI Opportunities Amid...
- 44 minutes ago
Microsoft (MSFT) Upgraded to Buy as Analysts Applaud AI and Azure Momentum